Catch up: Government shutdown averted in America; Christmas market attack in Germany



After days of chaos America's Senate voted to pass a new spending deal, averting a government shutdown. The proposal—which will fund the government through March and includes a \$110bn disaster-aid package—dropped a provision to extend America's debt ceiling, despite backing from Donald Trump to include it. In an earlier vote in the House of Representatives, most Republicans supported the deal, and no Democrats voted against it. President Joe Biden is expected to sign the bill into law on Saturday.

At least two people, including a child, were killed and dozens injured when a car drove into crowds at a Christmas market in Magdeburg, in **central Germany**. The suspected driver was arrested; he is said to be a doctor from Saudi Arabia who arrived in Germany in 2006, the premier of Saxony-Anhalt told German television. The motive for the attack has not been confirmed.

Volkswagen announced plans to cut more than 35,000 jobs, after striking a deal with labour unions. The German carmarker wants to streamline operations amid weaker demand and greater competition from Chinese firms. Previous attempts to cut costs had triggered massive strikes. Under the new agreement, no factories will close, but unions have consented to reduce the firm's workforce over the next five years.

Canada's prime minister, Justin Trudeau, looked set to lose power after Jagmeet Singh, a key ally, said he would introduce a noconfidence motion against the minority Liberal government when parliament reconvenes in the new year. Mr Singh's New Democratic Party has been propping up the Liberals. If his motion succeeds it would trigger an election. After nine years, voters have tired of Mr Trudeau's leadership; Canada's Conservatives lead the polls.

Ukrainian drones struck Kazan, a **Russian** city more than 1,000 kilometres from the border between the two countries. The attack damaged several buildings, and flights were temporarily halted at the city's airport, but no casualties were reported. Meanwhile some 113 Russian drones attacked Ukraine overnight. On Friday a Ukrainian attack on a town in Russia's Kursk region, using American-supplied weapons, killed six people.

Regulators in America approved the use of **Eli Lilly's** weight-loss drug to treat sleep apnoea. Zepbound becomes the first drug that can be prescribed to directly tackle the ailment, which afflicts around 23m Americans. Shares in Eli Lilly jumped on the news. Meanwhile, shares in its European rival, Novo Nordisk, slumped after it revealed disappointing results from tests of its latest obesity drug.

Eight people were convicted for offences pertaining to the murder of **Samuel Paty**, a **French** middle-school teacher, in 2020. Paty was beheaded by an Islamist extremist days after showing pupils

caricatures of the Prophet Muhammad during a class about freedom of expression. His killer was shot dead by police soon after. The defendants' crimes ranged from encouraging the attacker's actions on social media to providing him with weapons.

Word of the week: *ikejime*. The process used to kill the world's finest tuna sold at Toyosu market. Read the full story.

AI collects its awards



We are looking back on 2024. Today, science and technology.

It has been a big year for artificial intelligence models. For the first time ever, insights enabled by an AI model were deemed sufficiently significant to earn its developers one of the highest accolades in science: the Nobel prize in chemistry. The award jointly honoured the use of AI for protein-structure prediction and protein design.

Innovations that underpin machine learning, meanwhile, were awarded the physics prize (the definition of the field was stretched to include computer science). Geoffrey Hinton (pictured), one of the winners, mused that by assisting mental labour, generative AI might have as big an effect on society as the industrial revolution did by assisting physical labour. But he also fretted, as many in the field do, about how machine intelligence that outstripped the human variety would go on to treat its creators. For now, though, those creators are being treated very nicely indeed.

The everything drugs



First the drugs tackled diabetes. Then they took on obesity. Now GLP-1 receptor agonists like Ozempic are showing promise in treating unexpected conditions. This year they were approved in America to treat cardiovascular disease in overweight people. They are also being tested as therapies for Alzheimer's and addiction. As global demand for the drugs grows, pharma companies are racing to make them work as pills (rather than injections) and to reduce their side-effects.

How can GLP-1S do so much? In addition to acting in the gut, they also bind to receptors all over the body as well as in the brain. The drugs appear to reduce inflammation and interact with mechanisms linked to cravings and feelings of reward. Every new finding is helping researchers learn more about the workings of disease. It is early days yet, but GLP-1S may turn out to be one of the most successful classes of drugs in history.

Reasons to be hopeful about climate change



The climate news may seem grim. A global temperature record was set once again in 2024; there have been deadly disasters, from flooding to heatwaves; and negotiations at the COP29 climate talks made only modest progress.

Both activists and sceptics tend to agree on one thing: fighting for a stable climate is dauntingly expensive. *The Economist* looked at estimates of the global cost of an "energy transition" to a zero-emissions world. They range from around \$3trn to almost \$12trn a year. Yet we found that most analysts overestimate energy demand, underestimate technological advances and exaggerate the cost. In fact, renewables are getting cheaper every year. We calculated that the investment needed to meet new energy demand with clean technology, rather than without it, appears to be less than 1% of the world's GDP. Climate change is a real and difficult problem, but one that can be curbed affordably.

Solving a nutritional mystery



Processing innovations have made food cheaper, tastier and more convenient. But concerns are growing that these methods may be harmful to those who eat them. Most hotly debated are "ultraprocessed foods", which are packed with high concentrations of fat, sugar and salt. At the heart of the debate is a question: are UPFs unhealthy because their nutritional content is poor, or does the processing somehow pose risks in itself? This year scientists took a step towards solving the mystery.

The key is a randomised controlled trial, a form of experiment where researchers can track a person's food intake and control for all other variables. Few have been done in this field, but Kevin Hall, a researcher at America's National Institutes of Health, is currently leading one. The full results are expected next year. They could help refine the understanding of UPFs and pave the way for more balanced and useful guidelines.

The winners of this week's quiz



1112 720110111191

Thank you to everyone who took part in this week's quiz. The winners, chosen at random, were:

Iker Urrutia, Bermeo, SpainStefano Colombu, Ang Mo Kio, SingaporeHugh, Judith & Emma Tinsley, Wells, Britain

They all gave the correct answers of: George Michael, Edward Cullen, George Foreman, Elizabeth Barrett Browning and Charles Schulz. The theme is the regnal names of the last five British monarchs: George V, Edward VIII, George VI, Elizabeth II and Charles III.

The questions were:

Monday: Which famous singer died on Christmas Day 2016?

Tuesday: Which character marries Bella Swan in the Twilight book and film series?

Wednesday: Which heavyweight boxer made a fortune promoting a grill after retirement?

Thursday: Which Victorian poet had a secret courtship and marriage with the writer Robert Browning?

Friday: Which artist drew the Peanuts cartoon strip?

ikejime

The process used to kill the world's finest tuna sold at Toyosu market.

Read the full story.

The few wonders of the world only exist while there are those with the sight to see them.

Charles de Lint